NO20006431L - Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom - Google Patents

Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom

Info

Publication number
NO20006431L
NO20006431L NO20006431A NO20006431A NO20006431L NO 20006431 L NO20006431 L NO 20006431L NO 20006431 A NO20006431 A NO 20006431A NO 20006431 A NO20006431 A NO 20006431A NO 20006431 L NO20006431 L NO 20006431L
Authority
NO
Norway
Prior art keywords
composition
prevent
menopausal syndrome
changes due
treat osteoporosis
Prior art date
Application number
NO20006431A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006431D0 (no
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of NO20006431D0 publication Critical patent/NO20006431D0/no
Publication of NO20006431L publication Critical patent/NO20006431L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO20006431A 1998-06-23 2000-12-15 Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom NO20006431L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000417A IT1299191B1 (it) 1998-06-23 1998-06-23 Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa
PCT/IT1999/000174 WO1999066913A2 (en) 1998-06-23 1999-06-17 Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein

Publications (2)

Publication Number Publication Date
NO20006431D0 NO20006431D0 (no) 2000-12-15
NO20006431L true NO20006431L (no) 2001-02-22

Family

ID=11406005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006431A NO20006431L (no) 1998-06-23 2000-12-15 Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom

Country Status (27)

Country Link
US (1) US6335038B1 (da)
EP (1) EP1089742B1 (da)
JP (1) JP4430233B2 (da)
KR (1) KR20010071541A (da)
CN (1) CN1306434A (da)
AR (1) AR018924A1 (da)
AT (1) ATE228367T1 (da)
AU (1) AU755272B2 (da)
BR (1) BR9911440A (da)
CA (1) CA2334875C (da)
DE (1) DE69904172T2 (da)
DK (1) DK1089742T3 (da)
EE (1) EE200000741A (da)
ES (1) ES2188177T3 (da)
HU (1) HU224957B1 (da)
IL (1) IL140163A0 (da)
IS (1) IS5764A (da)
IT (1) IT1299191B1 (da)
MA (1) MA26655A1 (da)
NO (1) NO20006431L (da)
NZ (1) NZ508877A (da)
PL (1) PL192118B1 (da)
PT (1) PT1089742E (da)
SK (1) SK19292000A3 (da)
TN (1) TNSN99132A1 (da)
TR (1) TR200003735T2 (da)
WO (1) WO1999066913A2 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1302863B1 (it) * 1998-11-13 2000-10-10 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un
US6476010B2 (en) * 2000-03-10 2002-11-05 Hill's Pet Nutrition Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
US20010039296A1 (en) * 2000-03-23 2001-11-08 Debasis Bagchi Method and composition for preventing or reducing the symptoms of menopause
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US20020076470A1 (en) 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
IT1317079B1 (it) 2000-12-21 2003-05-26 Sigma Tau Ind Farmaceuti Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi.
IL157367A0 (en) * 2001-03-09 2004-02-19 Nestle Sa Composition improving age-related physiological deficits and increasing longevity
EP1370257B1 (en) * 2001-03-15 2007-07-25 DSM IP Assets B.V. COMPOSITION FOR THE PREVENTION OF OSTEOPOROSIS consisting of A COMBINATION OF ISOFLAVONES AND POLYUNSATURATED FATTY ACIDS
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
AU2003207429A1 (en) * 2002-02-15 2003-09-04 N.V. Nutricia Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k
KR100542478B1 (ko) * 2002-08-28 2006-01-11 한경대학교 산학협력단 석류 유래 피토에스트로겐을 함유하는 건강기능식품
WO2004026287A1 (en) * 2002-09-09 2004-04-01 Nestec S.A. Orally administrable composition for improving skin quality
KR100520408B1 (ko) * 2003-03-25 2005-10-10 주식회사 태평양 비만개선용 조성물
KR101143719B1 (ko) * 2003-05-27 2012-05-09 디에스엠 아이피 어셋츠 비.브이. 신규한 기능식품 조성물 및 그의 용도
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
CA2553884C (en) * 2004-01-28 2013-06-25 Nestec S.A. Nutritional composition for improving skin condition and preventing skin diseases
WO2005074905A1 (ja) 2004-02-03 2005-08-18 Kotosugi Inc. 雲南紅豆杉由来イソタキシレシノールを成分とする骨粗しょう症治療・予防薬
CA2559974C (en) * 2004-03-17 2012-08-14 Nestec S.A. Compositions and methods for reducing or preventing obesity
CN100351248C (zh) * 2004-07-05 2007-11-28 南京大学 染料木素衍生物及其制法和用途
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
DE102004060314A1 (de) * 2004-12-08 2006-08-31 Beiersdorf Ag Wirkstoffkombinationen aus einem oder mehreren Isoflavonoiden und Carnitin und/oder einem oder mehreren Acyl-Carnitinen
JP2008525528A (ja) 2004-12-29 2008-07-17 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における学習および／または記憶の衰退を抑制するための方法
BRPI0519851A2 (pt) * 2005-01-10 2017-05-30 Hormos Medical Ltd uso de uma lignana para a manufatura de uma composição para prevenir ou aliviar os sintomas relacionados à deficiência de estrogênio
RS52735B (en) * 2005-07-08 2013-08-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. APPLICATION OF A COMBINATION CONTAINING L-CARNITINE OR ALKANOIL L-CARNITINE, OIL-SOLUBLE OIL-BENZOQUINON AND OMEGA-3-POLYESATURATED FATTY ACID FOR PREPARATION OF NUTRITION OR MEDICINAL PRODUCTS
JP5284087B2 (ja) 2005-07-14 2013-09-11 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物の生命を延長するための方法
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
KR20080068850A (ko) * 2005-10-14 2008-07-24 디에스엠 아이피 어셋츠 비.브이. 레스베라트롤을 포함하는 기능성식품 조성물의 신규한 용도
US8226973B2 (en) * 2005-11-02 2012-07-24 Nestec, S. A. Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use
ES2604656T3 (es) 2006-02-28 2017-03-08 Nestec S.A. Composiciones y métodos para inducir crecimiento óseo e inhibir pérdida ósea
JP2009536610A (ja) * 2006-02-28 2009-10-15 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 骨疾患の予防／治療のための医薬組成物及びその調製方法
WO2007116052A1 (en) * 2006-04-12 2007-10-18 Unilever Plc Oral composition comprising dha and genistein for enhancing skin properties
PL2189155T3 (pl) * 2006-04-12 2016-07-29 Unilever Nv Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
ES2391305T3 (es) * 2006-04-12 2012-11-23 Unilever N.V. Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel
US20080108696A1 (en) 2006-08-02 2008-05-08 Brinton Roberta D Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
US8680140B2 (en) * 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
US20080200441A1 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators associated pharmaceutical compositions and methods of use
BRPI0918134B1 (pt) 2008-09-10 2019-02-12 Kaken Pharmaceutical Co., Ltd Derivado de prostaglandina i2
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
AU2009315771A1 (en) * 2008-11-11 2010-05-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
KR101158856B1 (ko) 2009-05-12 2012-06-25 한국생명공학연구원 콩잎 추출물 또는 이의 분획물을 유효성분으로 함유하는 비만, 고지혈증, 동맥경화, 지방간, 당뇨 또는 대사증후군의 예방 또는 치료용 조성물
CN102917703B (zh) * 2010-03-08 2015-08-19 科研制药株式会社 新型ep4激动剂
ES2670836T3 (es) * 2010-06-16 2018-06-01 Alfasigma S.P.A. Acetil-carnitina para uso en un método para incrementar la neurogénesis en el tejido neuronal
WO2012011572A1 (ja) * 2010-07-23 2012-01-26 国立大学法人大阪大学 拡張不全型心不全治療薬
IT201700116392A1 (it) * 2018-04-03 2019-10-03 Composizione per somministrazione orale aventi benefico effetto sulla salute della donna in menopausa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
JP2001511153A (ja) * 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン 血管変性性疾患の予防および処置のための組成物および方法

Also Published As

Publication number Publication date
AR018924A1 (es) 2001-12-12
CA2334875C (en) 2009-05-12
JP4430233B2 (ja) 2010-03-10
IT1299191B1 (it) 2000-02-29
DK1089742T3 (da) 2003-03-24
HUP0102879A2 (hu) 2002-03-28
ATE228367T1 (de) 2002-12-15
TR200003735T2 (tr) 2001-03-21
PT1089742E (pt) 2003-04-30
SK19292000A3 (sk) 2001-08-06
CN1306434A (zh) 2001-08-01
EP1089742B1 (en) 2002-11-27
WO1999066913A3 (en) 2000-04-20
KR20010071541A (ko) 2001-07-28
MA26655A1 (fr) 2004-12-20
PL345030A1 (en) 2001-11-19
DE69904172T2 (de) 2003-08-28
JP2002518437A (ja) 2002-06-25
ITRM980417A1 (it) 1999-12-23
PL192118B1 (pl) 2006-09-29
NO20006431D0 (no) 2000-12-15
DE69904172D1 (de) 2003-01-09
IS5764A (is) 2000-12-08
CA2334875A1 (en) 1999-12-29
US6335038B1 (en) 2002-01-01
HUP0102879A3 (en) 2002-12-28
AU4390999A (en) 2000-01-10
EE200000741A (et) 2002-04-15
HU224957B1 (en) 2006-04-28
ES2188177T3 (es) 2003-06-16
WO1999066913A2 (en) 1999-12-29
TNSN99132A1 (fr) 2005-11-10
IL140163A0 (en) 2002-02-10
NZ508877A (en) 2002-09-27
BR9911440A (pt) 2001-03-20
EP1089742A2 (en) 2001-04-11
AU755272B2 (en) 2002-12-05
ITRM980417A0 (it) 1998-06-23

Similar Documents

Publication Publication Date Title
NO20006431L (no) Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom
WO2000011968A8 (en) ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID
DK1064009T3 (da) Anvendelse af ekstrakter af irisplanter og Cimicifuga racemosa og tectorigenin som estrogenagtigt organselektivt lægemiddel uden uterotrop virkning
NO20006430L (no) Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner
BR0109912A (pt) Novas combinações antelmìnticas
FI951856A0 (fi) Farmaseuttinen koostumus osteoporoosin hoitamiseksi
NO20021640L (no) Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Gingo biloba
TR200003737T1 (tr) Diyet takviyesi ya da ilaç olarak kullanılan bileşim
WO2000007581A3 (en) Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid
AU5634500A (en) Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis
NO20013787D0 (no) Soyaekstrakt som inneholder lipider, fremgangsmåte for dets fremstilling og farmasöytiske og kosmetiske blandinger
WO2000000183A3 (en) Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin
TR200101344T2 (tr) Propionil L-karnitinden ve bir flavonoid'den oluşan antioksidan bileşim
Tejada et al. Quercetin effects on exercise induced oxidative stress and inflammation
ATE239504T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von störungen aufgrund von abnormalen fettstoffmetabolismus, enthaltend l-carnitin und chitosan
NO952601L (no) Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser
ATE339962T1 (de) Zubereitungen zur behandlung von lupus
TR200200015T2 (tr) L-Karnitin ve türevleri ile crataegus ekstreleri içeren kardiyoaktif bileşim
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia
KR940003550A (ko) 노인성 치매 예방 및 치료방법

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application